AIR POLLUTION AND ITS IMPACT ON INTERSTITIAL LUNG DISEASES: A NARRATIVE REVIEW

Santanu Kumar Ghosh [1], Ankit Chandra[2]

Received:- 16/09/2023
Revised:- 26/09/2023
Accepted:- 29/09/2023

Address for Correspondence:
1 , MD DTCD FICP, Associate Professor & HOD PG, Department of Respiratory Medicine, JLNMCH Bhagalpur, Bihar, India
2. PG Student, Department of Respiratory Medicine JLNMCH, Bhagalpur, Bihar, India

ABSTRACT

Background: Lung cancer and other respiratory illnesses, such as chronic obstructive pulmonary disease (COPD), are known to be exacerbated by air pollution. Its role in the pathogenesis of interstitial lung diseases (ILDs) is an area of growing interest and concern. *Objective*: This narrative review aims to synthesize the existing literature on the potential link between air pollution and various forms of ILD, highlighting key findings and identifying gaps in the current understanding. *Review Summary*: ILDs such hypersensitivity pneumonitis (HP), pneumoconiosis, and idiopathic pulmonary fibrosis (IPF) have been linked to air pollution in more recent research. The precise processes by which air pollution cause these diseases to manifest or worsen, however, are still unknown. While certain environmental factors have been connected to particular ILDs, such as IPF, there is little and unclear information available about other types of ILD. Taking into account different contaminants and their possible biological effects, this review investigates how air pollution may function as an etiological element in the development and worsening of ILD. *Future Implications*: Understanding the role of air pollution in ILD development and progression is crucial for both preventative and therapeutic strategies. This knowledge could guide clinical policies aimed at reducing exposure to harmful pollutants, thereby potentially decreasing the incidence and severity of ILD exacerbations. *Clinical Policy and Development*: The findings of this review underscore the need for heightened clinical awareness of the impact of air pollution on ILD. This has implications for public health policies, patient education, and the development of strategies to mitigate exposure to air pollutants, particularly in populations at risk of or already suffering from ILD. *Keywords: Air Pollution, Interstitial Lung Disease, Environmental Health, Respiratory Pathology.*

INTRODUCTION

Globally, air pollution—a complicated mixture of gases, particulate matter, and biological molecules—has become a major environmental health hazard. Numerous studies have demonstrated the link between air pollution and a variety of respiratory conditions, including lung cancer, asthma, and chronic obstructive pulmonary disease (COPD) [1]. Its effect on respiratory health is well-documented. However, because of its complex and frequently overlooked character, the link between air pollution and interstitial lung disorders (ILDs) deserves further investigation.

A wide range of lung conditions known as interstitial lung diseases are distinguished by inflammation and scarring of the lung interstitium. This group include diseases such as hypersensitivity pneumonitis (HP), pneumoconiosis, and idiopathic pulmonary fibrosis (IPF), which have different etiologies but similar pathogenetic pathways. The role of environmental factors, including air pollution, in the development and exacerbation of ILDs is gaining attention in the medical community [2].

Recent epidemiological studies have started to unveil the potential links between air pollution and the incidence and progression of ILDs. For instance, research indicated a correlation between increased levels of particulate matter and the exacerbation of IPF symptoms [3]. Similarly, a significant relation between air pollutants and the development of HP in susceptible populations was observed.

Despite these advancements, the pathophysiological mechanisms by which air pollution contributes to ILD remain incompletely understood. It is hypothesized that inhaled pollutants may trigger inflammatory and fibrotic pathways in the lungs, leading to tissue damage and scarring. The variability in individual susceptibility, along with the diverse nature of air pollutants, adds complexity to this association.

This review aims to comprehensively analyze the current literature on the impact of air pollution on ILDs, exploring both the epidemiological evidence and the proposed biological mechanisms. Additionally, it seeks to address the clinical and public health implications of this association, offering insights for future research and policy development in this vital area of environmental and respiratory health.

METHODOLOGY

A comprehensive and systematic search of the literature to gather and analyze relevant studies in the field was conducted. The primary objective was to consolidate existing research on the impact of air pollution on various forms of ILDs. A thorough literature search was conducted in PubMed, a widely recognized database for scientific publications.

Access this article online

Website:
www.onlinepjm.com

Quick Response Code

How to cite this article:

K. G. Santanu, C Ankit
Air Pollution And Its Impact On Interstitial Lung Diseases: A Narrative Review

The search terms used were combinations of "air pollution" or "pollution" with specific ILD-related terms: "interstitial lung diseases", "pulmonary fibrosis", "diffuse parenchymal lung disease", "idiopathic pulmonary fibrosis", and "hypersensitivity pneumonitis". This strategy ensured comprehensive capture of relevant literature. The search was restricted to studies published in the English language.

Included in the review were studies that specifically analyzed the effects of air pollution exposure on ILD. This encompassed research following subjects with lung radiology and spirometry assessments and multi-center prospective longitudinal cohort studies, particularly those demonstrating associations between particulate matter exposure and exacerbation or mortality in IPF patients. Studies not directly assessing the relationship between air pollution and ILDs were excluded. Research articles focusing exclusively on other respiratory diseases without implications for ILDs were not considered. Initial search results were screened for relevance by reviewing titles and abstracts. Full-text articles were then reviewed to confirm applicability to the review's objectives. A narrative synthesis of the findings was performed, summarizing, and discussing key results and conclusions from the selected studies.

CONSTITUENTS OF AIR POLLUTION

Air pollution is a complex mixture of various constituents, each with distinct sources and health effects. Understanding these components is crucial for comprehending the relationship between air pollution and interstitial lung diseases (ILDs). The major constituents of air pollution include particulate matter (PM), sulfur dioxide (SO_2), nitrogen oxides (NOx), ozone (O_3), and volatile organic compounds (VOCs).

Particulate Matter (PM): PM is a mixture of microscopic particles and liquid droplets that contains a range of elements, such as dust, metals, organic compounds, and acids. PM10 (particles that with a diameter of 10 micrometers or less) and PM2.5 (small particles with a diameter of 2.5 micrometers or less) are the two main categories used to group them according to size. Due to its capacity to deeply pierce lung tissue and perhaps induce inflammation as well as exacerbate respiratory conditions, PM2.5 is especially dangerous [4].

Nitrogen Oxides (NOx): NOx, particularly nitrogen dioxide (NO_2), is a prominent air pollutant produced primarily from fuel combustion. It is a known respiratory irritant and has been linked to lung function impairment and increased susceptibility to pulmonary infections [5].

Sulfur Dioxide (SO_2): SO_2 is primarily produced from the burning of fossil fuels containing sulfur compounds. It can cause bronchoconstriction and aggravate existing respiratory conditions, particularly in individuals with asthma or chronic lung diseases.

Ozone (O_3): Ground-level O_3, a key component of urban smog, is formed when NOx and VOCs react in the presence of sunlight. Ozone exposure can lead to various respiratory symptoms, decrease lung function, and exacerbate lung diseases [6].

Volatile Organic Compounds (VOCs): Certain solids or liquids, such as paints, cleaning products, and automobile emissions, release VOCs as gases. Some VOCs are known to have adverse health effects, including respiratory irritation and long-term damage to lung tissue. Each of these pollutants can individually or synergistically contribute to the pathogenesis or exacerbation of ILDs. The specific mechanisms by which these pollutants affect lung tissues vary but generally involve inflammatory and oxidative stress pathways leading to tissue damage and fibrosis. Additionally, the combined effect of these pollutants, as typically found in urban environments, poses a significant risk for the development and progression of ILDs.

INTERSTITIAL LUNG DISEASES (ILDS)

Recent advancements in the study of interstitial lung diseases (ILDs) have provided a more comprehensive understanding of these complex pulmonary conditions. ILDs encompass a diverse group of lung disorders characterized by inflammation and fibrosis of the lung interstitium, which can lead to significant morbidity and mortality.

One of the notable developments in recent years is the improved understanding of the epidemiology and etiology of ILDs. Studies have shown that the incidence and prevalence of ILDs vary globally, with IPF being one of the most common forms. An increasing trend in the incidence of IPF, particularly in industrialized countries, suggesting a possible link with environmental and occupational exposures [7].

Advances in genetic research have also shed light on the pathogenesis of ILDs. Genetic predispositions, as well as epigenetic modifications, have been implicated in the development of various forms of ILDs. A study identified several genetic markers associated with an increased risk of developing ILDs, providing new insights into potential therapeutic targets [8].

In terms of diagnosis, there has been significant progress in imaging and biomarker research. High-resolution computed tomography (HRCT) remains a cornerstone in the diagnosis of ILDs,

with recent improvements in imaging techniques allowing for more precise characterization of lung abnormalities. Biomarker studies have identified several circulating proteins and genetic markers that can aid in the diagnosis and prognostication of ILDs, potentially leading to more personalized treatment approaches [9].

Treatment of ILDs has also seen advancements, with the development of new pharmacological therapies aimed at slowing disease progression. Antifibrotic agents, such as pirfenidone and nintedanib, have become standard treatments for IPF. These drugs have shown efficacy in reducing the rate of decline in lung function and improving quality of life for patients with IPF.

Moreover, the role of pulmonary rehabilitation and supplemental oxygen therapy in managing ILDs has gained more recognition. Patients with ILDs who engaged in pulmonary rehabilitation programs have experienced improvements in exercise capacity, symptom management, and overall quality of life.

However, despite these advances, challenges remain in the management of ILDs. The heterogeneity of these diseases makes diagnosis and treatment complex, and there is still a need for further research into more effective therapeutic strategies and better understanding of the disease mechanisms.

Recent data on ILDs have brought significant improvements in understanding, diagnosing, and treating these complex diseases. The advancements in genetic research, imaging techniques, and new therapeutic agents mark a significant step forward in the field, offering hope for better management and outcomes for patients with ILDs.

AIR POLLUTION AND LUNG TRANSPLANTATION

The intersection of air pollution and lung transplantation outcomes has garnered significant attention in recent years, particularly due to the increasing prevalence of both air pollution and lung transplants globally. Lung transplantation, often a life-saving intervention for patients with severe lung diseases including interstitial lung diseases (ILDs), presents various challenges in the post-transplant period. These challenges, ranging from infection and rejection to the effects of environmental factors like air pollution, have profound implications for both the pre- and post-transplant phases.

In the pre-transplant phase, exposure to air pollution for candidates awaiting lung transplantation can significantly affect their health status. Recent studies have highlighted that pre-transplant exposure to high levels of air pollutants, particularly fine particulate matter (PM2.5) and nitrogen dioxide (NO_2), is associated with poorer baseline lung function and an increased burden of comorbidities. This exposure can have critical implications for transplant eligibility and subsequent outcomes.

Following lung transplantation, patients face a heightened risk of complications. One of the major concerns is chronic lung allograft dysfunction (CLAD), a leading cause of morbidity and mortality in post-transplant patients. Emerging research suggests that exposure to air pollutants can exacerbate these risks. Pollutants like particulate matter are linked to increased inflammation and oxidative stress in transplanted lungs, potentially accelerating CLAD development [10].

Moreover, the long-term outcomes of lung transplant recipients can be adversely affected by sustained exposure to air pollution. A study indicated that patients residing in areas with higher levels of pollution had a higher risk of transplant rejection and lower overall survival rates compared to those in less polluted environments [11]. These findings underscore the importance of considering environmental factors in post-transplant care.

Consequently, there is a growing focus on developing strategies to monitor and minimize exposure to air pollution for lung transplant recipients. This includes educating patients about air quality, using air purifiers, and potentially incorporating air quality considerations into post-transplant care management.

However, there is still a need for more comprehensive and long-term studies to fully understand air pollution's impact on lung transplant patients. This includes its effects during the pre-transplant period, immediately after transplantation, and in long-term post-transplant care. Recent data underscores the critical importance of air pollution as a factor influencing both the candidacy and outcomes of lung transplantation, highlighting the need for integrating environmental health considerations into the care and management of lung transplant patients.

PATHOPHYSIOLOGICAL MECHANISMS OF INTERSTITIAL LUNG DISEASES

Recent advancements in understanding the pathophysiological mechanisms underlying interstitial lung diseases (ILDs) have been significant, offering deeper insights into these complex pulmonary conditions. ILDs comprise a spectrum of conditions marked by differing degrees of lung interstitium inflammation and fibrosis, leading to impaired lung function and reduced oxygen transfer.

Inflammation and Immune Response: A key area of recent research has focused on the role of inflammation and the immune system in the pathogenesis of ILDs. Studies suggest that an aberrant immune response, triggered by environmental exposures, infections, or autoimmunity, plays a critical role in the development of many ILDs. For instance, involvement of pro-inflammatory cytokines and immune cells in the pulmonary inflammation seen in ILDs, suggesting potential targets for therapeutic intervention [12].

Fibrosis and Tissue Remodeling: Fibrosis, the hallmark of ILDs, involves excessive deposition of extracellular matrix components in the lung tissue, leading to scarring and stiffening of the lungs. Recent data have shed light on the molecular pathways involved in fibrogenesis. The transforming growth factor-beta (TGF-β) pathway, in particular, has been identified as a key driver of fibrosis, with several studies exploring ways to modulate this pathway to halt or reverse lung scarring [13].

Epigenetic and Genetic Factors: Advancements in genomics and epigenetics have revealed the importance of genetic predisposition and epigenetic modifications in the development of ILDs. For example, mutations in genes related to telomere maintenance, surfactant production, and host defense have been linked to familial forms of ILD. Furthermore, epigenetic changes such as DNA methylation and histone modification have been implicated in the regulation of genes involved in inflammation and fibrosis [14].

Oxidative Stress and Cellular Senescence: It has been established that oxidative stress, which arises from an imbalance between pro-oxidants and antioxidants, plays a role in the pathophysiology of inflammatory lung diseases. An increasing amount of research suggests that oxidative stress can cause cellular senescence and damage, which can then cause inflammation and fibrosis in the lung tissue.

Vascular Alterations and Hypoxia: Vascular remodeling and hypoxia are also critical factors in the pathophysiology of ILDs. Hypoxia, or reduced oxygen levels in the lung tissue, can exacerbate fibrosis and inflammation. Research has demonstrated the impact of altered lung vasculature and hypoxia on disease progression in ILDs, suggesting potential areas for therapeutic intervention [15].

CONCLUSION

The interplay between air pollution and ILDs presents a significant public health challenge. It calls for a concerted effort from researchers, clinicians, and policymakers to mitigate the impact of environmental pollutants on lung health and to improve outcomes for individuals with ILDs. This review serves as a call to action for increased awareness, research, and policy initiatives aimed at reducing the burden of ILDs and improving the quality of life for those affected by these debilitating diseases.

ACKNOWLEDGMENT

The authors extend their gratitude to fellow researchers, healthcare professionals, study participants, mentors, and their support networks for their invaluable contributions and unwavering support in advancing our understanding of the impact of air pollution in Interstitial Lung Diseases. The collaborative efforts of the scientific community, funding agencies, and regulatory authorities are essential in enhancing air quality levels worldwide through research in this field.

List of abbreviations:

COPD - Chronic Obstructive Pulmonary Disease
ILDs - Interstitial Lung Diseases
HP - Hypersensitivity Pneumonitis
IPF - Idiopathic Pulmonary Fibrosis
PM - Particulate Matter
NOx - Nitrogen Oxides
NO_2 - Nitrogen Dioxide
SO_2 - Sulfur Dioxide
O_3 - Ozone
VOCs - Volatile Organic Compounds
CLAD - Chronic Lung Allograft Dysfunction
HRCT - High-Resolution Computed Tomography
TGF-β - Transforming Growth Factor-Beta

Source of funding: No funding received.
Conflict of interest: The authors have no competing interests to declare.

REFEERENCES

1. Viegi G, Maio S, Fasola S, Baldacci S. Global burden of chronic respiratory diseases. Journal of aerosol medicine and pulmonary drug delivery. 2020 Aug 1;33(4):171-7.
2. Park Y, Ahn C, Kim TH. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses. Scientific Reports. 2021 Mar 2;11(1):4318.
3. Kyung SY, Jeong SH. Particulate-matter related respiratory diseases. Tuberculosis and respiratory diseases. 2020 Apr;83(2):116.
4. Kim D, Chen Z, Zhou LF, Huang SX. Air pollutants and early origins of respiratory diseases. Chronic Dis Transl Med. 2018;4(2):75–94.
5. yyagari VN, Januszkiewicz A, Nath J. Pro-inflammatory responses of human bronchial epithelial cells to acute nitrogen dioxide exposure. Toxicology. 2004;197:149–64.

6. Alexis NE, Lay JC, Hazucha M, et al. Low-level ozone exposure induces airways inflammation and modifies cell surface phenotypes in healthy humans. Inhal Toxicol. 2010;22(7):593–600.
7. Rivera-Ortega P, Molina-Molina M. Interstitial lung diseases in developing countries. Annals of Global Health. 2019;85(1).
8. Adegunsoye A, Vij R, Noth I. Integrating genomics into management of fibrotic interstitial lung disease. Chest. 2019 May 1;155(5):1026-40.
9. Inoue Y, Kaner RJ, Guiot J, Maher TM, Tomassetti S, Moiseev S, Kuwana M, Brown KK. Diagnostic and prognostic biomarkers for chronic fibrosing interstitial lung diseases with a progressive phenotype. Chest. 2020 Aug 1;158(2):646-59.
10. Supphapipat K, Leurcharusmee P, Chattipakorn N, Chattipakorn SC. Impact of air pollution on postoperative outcomes following organ transplantation: Evidence from clinical investigations. Clinical Transplantation. 2023:e15180.
11. Supphapipat K, Leurcharusmee P, Chattipakorn N, Chattipakorn SC. Impact of air pollution on postoperative outcomes following organ transplantation: Evidence from clinical investigations. Clinical Transplantation. 2023:e15180.
12. Montero P, Milara J, Roger I, Cortijo J. Role of JAK/STAT in interstitial lung diseases; molecular and cellular mechanisms. International journal of molecular sciences. 2021 Jun 9;22(12):6211.
13. Gharaee-Kermani M, Hu B, Phan SH, Gyetko MR. Recent advances in molecular targets and treatment of idiopathic pulmonary fibrosis: focus on TGFβ signaling and the myofibroblast. Current medicinal chemistry. 2009 Apr 1;16(11):1400-17.
14. Travis W, Costabel U, Hansell D, Lederer D, Martinez F, García-Sancho C, Buendía-Roldán I, Fernández-Plata M, Steele M, Speer M, Loyd J. Familial interstitial lung disease. Seminars in respiratory and critical care medicine 2020 Apr 1 (Vol. 41, No. 02, pp. 229-237). 333 Seventh Avenue, New York, NY 10001, USA.: Thieme Medical Publishers.
15. Farkas L, Kolb M. Pulmonary microcirculation in interstitial lung disease. Proceedings of the American Thoracic Society. 2011 Nov 1;8(6):516-21.

***